Journal: Nucleic Acids Research

Article Title: Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy

doi: 10.1093/nar/gkac491

Figure Lengend Snippet: Targeting of p100/p52 promotes a transcriptional downregulation of RAD51 and other proteins known to control DSB repair by HR. RNA-seq was performed on U2OS cells transfected with non-silencing (NS), NFKB2 or RELB siRNA. ( A ) Knockdown is efficient for both p100/52 and RelB, based on mRNA measurements by RNA-seq (left) and protein level by western blot (right). ( B ) KEGG pathway analysis of was performed to predict the 10 most upregulated and 10 most downregulated pathways in response to siNFKB2. Corresponding effects in response to siRELB are also displayed. ( C ) Expression levels are displayed for 39 genes with known relevance to HR, as defined by the KEGG database. Genes are arrayed from left to right based on degree of expression change after siNFKB2 (* denotes P < 0.01).

Article Snippet: The following primary antibodies were used: mouse anti-human NF-κB1 p105/p50 (Santa Cruz 8414), mouse anti-human NF-κB2 p100/p52 (Millipore 05–361), rabbit anti-human RelB (Cell Signaling Technology 4922), rabbit anti-human RAD51 (Pacific Immunology, affinity purified from serum and used at 1:1000), mouse anti-human 53BP1 (Upstate 05-726 Clone BP13), rabbit anti-human H2A.X (Abcam ab229914), mouse anti-human γH2A.X (Millipore 05–636), rabbit anti-human BRCA2 (Bethyl A303-434A), rabbit anti-human GAPDH (Cell Signaling Technology 5174), and mouse anti-chicken α-tubulin (Fitzgerald 10R-T130A).

Techniques: Control, RNA Sequencing, Transfection, Knockdown, Western Blot, Expressing

Journal: Nucleic Acids Research

Article Title: Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy

doi: 10.1093/nar/gkac491

Figure Lengend Snippet: Targeting of p100/p52 promotes downregulation of RAD51 protein. ( A ) Representative western blots demonstrate that transcriptional silencing of key NF-κB proteins leads to reduced levels of RAD51 protein. ( B ) Quantitation of western blots from three independent experiments demonstrate that RAD51 reductions after siNFKB2 are reproducible (error bars denote the SEM). ( C ) Comparable levels of RAD51 knockdown are observed using three different siRNAs (each at 25 nM) targeting NFKB2 in U2OS cells. ( D ) Forced overexpression of the p52 fragment of Nfkb2 in mouse lung tissue is associated with increased Rad51 expression (error bars denote standard error, * denotes P < 0.02, NS denotes non-silencing control).

Article Snippet: The following primary antibodies were used: mouse anti-human NF-κB1 p105/p50 (Santa Cruz 8414), mouse anti-human NF-κB2 p100/p52 (Millipore 05–361), rabbit anti-human RelB (Cell Signaling Technology 4922), rabbit anti-human RAD51 (Pacific Immunology, affinity purified from serum and used at 1:1000), mouse anti-human 53BP1 (Upstate 05-726 Clone BP13), rabbit anti-human H2A.X (Abcam ab229914), mouse anti-human γH2A.X (Millipore 05–636), rabbit anti-human BRCA2 (Bethyl A303-434A), rabbit anti-human GAPDH (Cell Signaling Technology 5174), and mouse anti-chicken α-tubulin (Fitzgerald 10R-T130A).

Techniques: Western Blot, Quantitation Assay, Knockdown, Over Expression, Expressing, Control

Journal: Nucleic Acids Research

Article Title: Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy

doi: 10.1093/nar/gkac491

Figure Lengend Snippet: Targeting of p100/p52 inhibits DNA damage-induced RAD51 focus formation in human cancer cells. Cells previously transfected with siRNA or non-silencing (NS) controls were pulse-labeled with EdU to mark S-phase cells and concomitantly treated with 30 nM CPT for 1 hour. Cells were harvested and immune-stained as indicated. Representative microscopic images of unselected nuclei ( A ) are displayed for cells collected 3-hours after CPT treatment, and ( B ) quantitation of RAD51 foci per nucleus is plotted for each of the indicated conditions. ( C ) Quantitation of EdU intensity in CPT-untreated cells is used to estimate cell cycle at the time of the EdU pulse. ( D ) A schematic representation of the treatment timeline is displayed. ( E ) The mean number of RAD51 foci per EdU-positive nucleus is plotted as a function of time following CPT treatment (error bars denote SEM for at least 100 nuclei within a single experimental replicate, * denotes P < 0.05, *** denotes P < 1e−13, and ns denotes P > 0.05).

Article Snippet: The following primary antibodies were used: mouse anti-human NF-κB1 p105/p50 (Santa Cruz 8414), mouse anti-human NF-κB2 p100/p52 (Millipore 05–361), rabbit anti-human RelB (Cell Signaling Technology 4922), rabbit anti-human RAD51 (Pacific Immunology, affinity purified from serum and used at 1:1000), mouse anti-human 53BP1 (Upstate 05-726 Clone BP13), rabbit anti-human H2A.X (Abcam ab229914), mouse anti-human γH2A.X (Millipore 05–636), rabbit anti-human BRCA2 (Bethyl A303-434A), rabbit anti-human GAPDH (Cell Signaling Technology 5174), and mouse anti-chicken α-tubulin (Fitzgerald 10R-T130A).

Techniques: Transfection, Labeling, Staining, Quantitation Assay